Structures by: Kiran Kumar H. A.
Total: 37
5-(2-Chlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazole-4-carbaldehyde
C17H13ClN2O2
Acta Crystallographica Section C (2019) 75, 6
a=10.3034(4)Å b=11.4856(4)Å c=14.4725(5)Å
α=81.013(2)° β=69.861(2)° γ=69.990(2)°
3-Methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazole-4-carbaldehyde
C21H16N2O2
Acta Crystallographica Section C (2019) 75, 6
a=7.7302(6)Å b=17.2550(16)Å c=13.1989(11)Å
α=90° β=106.079(2)° γ=90°
3-Methyl-5-(4-nitrophenoxy)-1-phenyl-1<i>H</i>-pyrazole-4-carbaldehyde
C17H13N3O4
Acta Crystallographica Section C (2019) 75, 6
a=14.1163(9)Å b=11.7268(7)Å c=9.3982(5)Å
α=90° β=94.259(3)° γ=90°
3-Methyl-1-phenyl-5-(piperidin-1-yl)-1<i>H</i>-pyrazole-4-carbaldehyde
C16H19N3O
Acta Crystallographica Section C (2019) 75, 6
a=8.9432(7)Å b=16.0546(14)Å c=10.1155(8)Å
α=90° β=97.777(2)° γ=90°
(3<i>RS</i>)-2-Acetyl-5-(4-azidophenyl)-5'-(2-chlorophenoxy)-3'-methyl-1'-phenyl-3,4-dihydro-1'<i>H</i>,2<i>H</i>-[3,4'-bipyrazole]
C27H22ClN7O2
Acta Crystallographica Section C (2019) 75, 6
a=10.8804(4)Å b=11.3363(4)Å c=11.5737(4)Å
α=97.294(2)° β=90.050(2)° γ=117.840(2)°
(3<i>RS</i>)-2-Acetyl-5-(4-azidophenyl)-3'-methyl-5'-(naphthalen-2-yloxy)-1'-phenyl-3,4-dihydro-1'<i>H</i>,2<i>H</i>-[3,4'-bipyrazole]
C31H25N7O2
Acta Crystallographica Section C (2019) 75, 6
a=10.4911(11)Å b=11.2048(12)Å c=13.5943(17)Å
α=105.323(3)° β=93.505(3)° γ=117.460(3)°
3-[5-(2-Chlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-[4-(prop-2-yn-1-yloxy)phenyl]prop-2-en-1-one
C28H21ClN2O3
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.909(7)Å b=10.193(6)Å c=12.024(8)Å
α=90.94(2)° β=106.27(2)° γ=92.75(2)°
3-[5-(4-Chlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-[4-(prop-2-yn-1-yloxy)phenyl]prop-2-en-1-one
C28H21ClN2O3
Acta Crystallographica Section E (2020) 76, 5 683-691
a=8.9959(14)Å b=9.7380(15)Å c=13.637(2)Å
α=95.901(4)° β=94.122(4)° γ=95.959(4)°
3-[3-Methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]-1-[4-(prop-2-ynyloxy)phenyl]prop-2-en-1-one
C32H24N2O3
Acta Crystallographica Section E (2020) 76, 5 683-691
a=8.8615(6)Å b=10.4973(7)Å c=13.6588(10)Å
α=79.006(3)° β=89.412(3)° γ=80.971(3)°
1-(4-Azidophenyl)-3-[3-methyl-5-(2-methylphenoxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-one
C26H21N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.8432(6)Å b=11.7441(7)Å c=12.3005(7)Å
α=114.120(2)° β=111.139(2)° γ=96.537(2)°
1-(4-Azidophenyl)-3-[5-(2,4-dichlorophenoxy)-3-methyl-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-one
C25H17Cl2N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=28.1916(17)Å b=8.0537(5)Å c=22.0446(12)Å
α=90° β=109.0700(10)° γ=90°
1-(4-Azidophenyl)-3-[3-methyl-5-(naphthalen-2-yloxy)-1-phenyl-1<i>H</i>-pyrazol-4-yl]prop-2-en-1-on
C29H21N5O2
Acta Crystallographica Section E (2020) 76, 5 683-691
a=9.8460(8)Å b=22.4303(18)Å c=11.0490(9)Å
α=90° β=104.157(2)° γ=90°
<i>N</i>-(4-Methoxyphenyl)piperazine
C11H16N2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.9683(7)Å b=7.9683(8)Å c=18.975(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 3,5-dinitrobenzoate
C11H17N2O,C7H3N2O6
Acta Crystallographica Section E (2020) 76, 4 488-495
a=7.4365(4)Å b=10.6276(6)Å c=13.2700(6)Å
α=92.238(4)° β=97.057(4)° γ=108.618(5)°
4-(4-Methoxyphenyl)piperazin-1-ium 2,4,6-trinitrophenolate
C11H17N2O,C6H2N3O7
Acta Crystallographica Section E (2020) 76, 4 488-495
a=8.7568(6)Å b=6.6292(5)Å c=34.024(2)Å
α=90° β=96.987(6)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-aminobenzoate monohydrate
C7H6NO2,C11H17N2O,H2O
Acta Crystallographica Section E (2020) 76, 4 488-495
a=6.2590(7)Å b=7.4549(9)Å c=19.269(2)Å
α=83.280(10)° β=84.7400(10)° γ=85.380(10)°
2-(4-Chlorobenzyl)-6-(4-fluorophenyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18ClFN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=15.3400(10)Å b=11.1619(7)Å c=15.3850(10)Å
α=90° β=119.480(10)° γ=90°
2-(4-Chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]-6-phenylimidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H19ClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=16.456(7)Å b=10.420(2)Å c=26.391(7)Å
α=90° β=90.031(12)° γ=90°
6-(4-Bromophenyl)-2-(4-chlorobenzyl)-5-[(1<i>H</i>-indol-3-yl)methyl]imidazo[2,1-<i>b</i>][1,3,4]thiadiazole
C26H18BrClN4S
Acta Crystallographica Section E (2020) 76, 1 18-24
a=9.5735(8)Å b=9.6860(9)Å c=25.644(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-bromobenzoate monohydrate
C11H17N2O,C7H4BrO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2004(8)Å b=7.4957(9)Å c=20.440(2)Å
α=85.080(10)° β=87.370(10)° γ=85.000(10)°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxybenzoate
C11H17N2O,C7H5O3
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.5009(8)Å b=7.9735(9)Å c=32.155(4)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 2-hydroxy-3,5-dinitrobenzoate
C7H3N2O7,C11H17N2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=7.5500(9)Å b=7.6489(9)Å c=32.719(6)Å
α=90° β=91.300(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogensuccinate
C11H17N2O,C4H5O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.3225(9)Å b=28.261(3)Å c=5.8228(8)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium pyridine-3-carboxylate
C11H17N2O,C6H4NO2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.2817(7)Å b=11.2905(7)Å c=30.309(2)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenfumarate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0690(10)Å b=28.528(3)Å c=5.8375(9)Å
α=90° β=90° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium hydrogenmaleate
C11H17N2O,C4H3O4
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.0630(10)Å b=6.4956(9)Å c=26.093(3)Å
α=90° β=93.180(10)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium trichloroacetate
C11H17N2O,C2Cl3O2
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=10.6117(11)Å b=13.8080(10)Å c=10.9137(8)Å
α=90° β=90° γ=90°
Bis(4-(4-methoxyphenyl)piperazin-1-ium) chloranilate(2-) dihydrate
C11H17N2O,0.5(C6Cl2O4),H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=9.1597(5)Å b=15.1434(8)Å c=10.8742(6)Å
α=90° β=102.067(5)° γ=90°
4-(4-Methoxyphenyl)piperazin-1-ium 4-chlorobenzoate monohydrate
C11H17N2O,C7H4ClO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2110(10)Å b=7.4810(10)Å c=20.144(4)Å
α=84.90(2)° β=87.48(2)° γ=85.19(2)°
4-(4-Methoxyphenyl)piperazin-1-ium benzoate monohydrate
C11H17N2O,C7H5O2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2150(10)Å b=7.5470(10)Å c=18.716(4)Å
α=84.34(2)° β=87.14(2)° γ=84.69(2)°
4-(4-Methoxyphenyl)piperazin-1-ium 4-fluorobenzoate monohydrate
C11H17N2O,C7H4FO2,H2O
Acta Crystallographica Section E (2019) 75, 10 1494-1506
a=6.2560(10)Å b=7.4890(10)Å c=19.097(2)Å
α=84.190(10)° β=86.98(2)° γ=84.62(2)°
1-Benzoyl-4-(4-methoxyphenyl)piperazine
C18H20N2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=29.403(5)Å b=7.9811(14)Å c=6.7898(13)Å
α=90° β=97.352(12)° γ=90°
1-(2-Fluorobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19FN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=6.998(2)Å b=7.938(2)Å c=28.415(6)Å
α=90° β=92.20(3)° γ=90°
1-(2-Chlorobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19ClN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=13.0320(11)Å b=13.2470(13)Å c=19.258(2)Å
α=90° β=90° γ=90°
1-(2-Iodobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19IN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=12.7671(13)Å b=13.5429(12)Å c=20.2542(16)Å
α=90° β=90° γ=90°
1-(2-Hydroxybenzoyl)-4-(4-methoxyphenyl)piperazine
C18H20N2O3
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=9.7265(6)Å b=12.9084(9)Å c=24.8610(10)Å
α=90° β=90° γ=90°
1-(2-Bromoobenzoyl)-4-(4-methoxyphenyl)piperazine
C18H19BrN2O2
Acta Crystallographica Section E (2019) 75, 8 1253-1260
a=12.9119(14)Å b=13.3664(16)Å c=19.5019(19)Å
α=90° β=90° γ=90°